In 33 patients with acute generalised pustular psoriasis flares, one recibokibart dose gave a pustulation subscore of 0 or 1 at week 1 in 86% vs 9% on placebo (P<0.001). Adverse events included hypoproteinaemia and hyperlipidaemia.
RCTn = 33
Yang et al. Efficacy and safety of recibokibart, an interleukin-36 receptor antibody, in generalized pustular psoriasis: a phase II randomized controlled trial